Sanofi American Depositary Receipt (SNY)
Summary
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
Sanofi: Trump's Vaccine Policy Won't Break The Story
On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.
Sanofi: How I Leveraged This Undervalued Dividend Aristocrat
Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.
Sanofi American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 18,034 | $899,199.03 | $771,494.52 | -$127,704.51 | -14.2% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 24 | $1,331 | $1,033.92 | -$297.08 | -22.32% |
 Curtis Ellergodt Rothschild Investment LLC | 3,909 | $193,953.39 | $167,657.01 | -$26,296.38 | -13.56% |
 Dodge & Cox Dodge & Cox Funds | 28.09M | $1.36B | $1.23B | -$128.28M | -9.46% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 125,461 | $5.35M | $5.45M | $100,344.06 | 1.87% |
Sanofi American Depositary Receipt (SNY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sanofi American Depositary Receipt ever had a stock split?
Sanofi American Depositary Receipt Profile
| Pharmaceuticals Industry | Healthcare Sector | Belén Garijo López CEO | NASDAQ (NGS) Exchange | 80105N105 CUSIP |
| FR Country | 76,493 Employees | 4 May 2026 Last Dividend | 30 Sep 2013 Last Split | - IPO Date |
Overview
Sanofi is a global leader in healthcare, deeply engaged in the journey of pushing the boundaries of medicine to improve health outcomes across the world. Founded in 1973 and headquartered in Paris, France, the company has evolved its name from Sanofi-Aventis to Sanofi in May 2011, marking a milestone in its expansive history. With a robust presence in the United States, Europe, and various international markets, Sanofi undertakes the research, development, manufacture, and marketing of therapeutic solutions through a comprehensive portfolio segmented into Pharmaceuticals, Vaccines, and Consumer Healthcare. The company's dedication to innovation is underscored by its collaborations, including a notable one with GlaxoSmithKline for a Covid-19 vaccine and a research venture with Stanford University School of Medicine focused on immunology and inflammation. Furthermore, Sanofi's partnership with Prellis Biologics, Inc., showcases its commitment to exploring new horizons in healthcare solutions.
Products and Services
- Specialty Care Products: Sanofi delivers cutting-edge treatments in various therapeutic areas. This includes human monoclonal antibodies, treatments for multiple sclerosis, neurology, inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders. These products underline Sanofi's commitment to addressing complex health conditions with innovative solutions.
- Diabetes and Cardiovascular Products: The company offers a range of medicines for diabetes care, showcasing its role in battling this global epidemic. Additionally, it provides products for cardiovascular health, emphasizing the importance of managing heart-related conditions.
- Vaccines: With an emphasis on public health, Sanofi supplies vaccines for poliomyelitis, pertussis, and Hib for children; influenza, adult boosters, meningitis, and vaccines for travel and endemic diseases for adults, highlighting its role in preventing infectious diseases across all age groups.
- Consumer Healthcare: Beyond prescription medicines, Sanofi extends its healthcare solutions to over-the-counter products. This includes allergy relief, cough and cold therapies, pain management, liver care, products promoting physical and mental wellness, probiotics, digestive health, and nutritional products. The range also features daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema, catering to a wide array of consumer health needs.
- Pharmaceutical Products and Vaccines in Development: Sanofi is actively involved in the development of new pharmaceuticals and vaccines, pointing to a future of continued innovation and enhanced healthcare solutions. This commitment to research and development ensures Sanofi remains at the forefront of addressing emerging health challenges.
